{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:57:13Z","timestamp":1782755833302,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinthera.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:50:56Z","timestamp":1737982256000},"page":"e1-e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vancomycin Dosing in Patients on Intermittent Hemodialysis\u2014A Retrospective Study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8113-2949","authenticated-orcid":false,"given":"Jacqueline","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Curtain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Salahudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kodgire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.001_bib0001","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.06.014","article-title":"Vascular access\u2013related infections: definitions, incidence rates, and risk factors","volume":"52","author":"Lafrance","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0002","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01590309","article-title":"Staphylococcus aureus infections in hemodialysis: what a nephrologist should know","volume":"4","author":"Vandecasteele","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0003","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ki.2010.35","article-title":"Recent changes in vancomycin use in renal failure","volume":"77","author":"Vandecasteele","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0004","unstructured":"Au E., Davies C., Bateman S., Chen J., Hurst K., Irish G., et al. 46th Report, Chapter 3: Mortality in Kidney Failure with Replacement Therapy. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia; 2023. p. 7-8. [cited 2024 Apr 24]. Available from: https:\/\/www.anzdata.org.au"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0005","first-page":"197","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients\u2014United States, 2005","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/587673","article-title":"The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals","volume":"46","author":"Kaye","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0007","unstructured":"Territory Pathology. Alice Springs Hospital 2024 Antibiogram (% Susceptible) [unpublished document]. Alice Springs: Territory Pathology; 2024"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1698-5","article-title":"The epidemiology of Staphylococcus aureus and Panton-Valentine leucocidin (PVL) in Central Australia, 2006-2010","volume":"16","author":"Hewagama","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0009","first-page":"462","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in Central Australia","volume":"30","author":"Stevens","year":"2006","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003070","article-title":"Non-communicable diseases, infection and survival in a retrospective cohort of Indigenous and non-Indigenous adults in central Australia","volume":"3","author":"Einsiedel","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0011","unstructured":"Irish G., Davies C., Au E., Bateman S., Chen J., Hurst K., et al. 46th Report, Chapter 1: Incidence of Kidney Failure with Replacement Therapy. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia; 2023. p. 6. [cited 2024 Apr 24]. Available at: http:\/\/www.anzdata.org.au"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0012","unstructured":"Au E., Davies C., Bateman S., Chen J., Hurst K., Irish G., et al. 46th Report, Chapter 2: Prevalence of Kidney Failure with Replacement Therapy. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia; 2023. p. 7. [cited 2024 Apr 24]. Available at: http:\/\/www.anzdata.org.au"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0013","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0277-9536(03)00243-0","article-title":"Exploring the pathways leading from disadvantage to end-stage renal disease for Indigenous Australians","volume":"58","author":"Cass","year":"2004","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0014","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcjd.2014.03.005","article-title":"The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes","volume":"38","author":"Dyck","year":"2014","journal-title":"Can J Diab"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0015","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.clinthera.2025.01.001_bib0016","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.001_bib0017","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","article-title":"Vancomycin: a 50-year reassessment","volume":"42","author":"Moellering","year":"2006","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2025.01.001_bib0018","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmi.2015.04.003","article-title":"Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis","volume":"21","author":"Steinmetz","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0019","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc1516","article-title":"Clinical review: use of vancomycin in hemodialysis patients","volume":"6","author":"Launay-Vacher","year":"2002","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0021","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/cir322","article-title":"Weight-based loading of vancomycin in patients on hemodialysis","volume":"53","author":"Brown","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0022","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ajhp\/61.17.1812","article-title":"Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm","volume":"61","author":"Pai","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0023","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.ajkd.2005.07.018","article-title":"Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis","volume":"46","author":"Ariano","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0024","first-page":"436","article-title":"Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study","volume":"65","author":"El Nekidy","year":"2012","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.clinthera.2025.01.001_bib0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1525-139X.2010.00803.x","article-title":"Vancomycin dosing in patients on intermittent hemodialysis","volume":"24","author":"Vandecasteele","year":"2011","journal-title":"Semin Dial"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0026","first-page":"569","article-title":"A protocolized approach to vancomycin dosing in conventional hemodialysis","volume":"23","author":"Panais","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0027","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2014United States, 2002","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0028","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nep.12270","article-title":"Vancomycin dosing nomogram for hemodialysis patients","volume":"19","author":"Jeremiah","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0029","first-page":"130","article-title":"Optimizing vancomycin dosage regimens in relation to high-flux hemodialysis","volume":"74","author":"Hui","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0031","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1053\/j.ajkd.2010.03.016","article-title":"Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience","volume":"55","author":"Taylor","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0032","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/cis458","article-title":"Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis","volume":"55","author":"Zelenitsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0033","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ki.1996.393","article-title":"Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy","volume":"50","author":"Barth","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0034","first-page":"15","article-title":"Vancomycin initial dosing in adult dialysis patients in a tertiary care hospital (VIDAD)","volume":"1","author":"Ramadas","year":"2021","journal-title":"Pharm Res Rep"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/0886022X.2016.1229992","article-title":"Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients","volume":"38","author":"Maxson","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0036","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration\u2013time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteremia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0037","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijantimicag.2017.12.017","article-title":"Vancomycin dosing in chronic high-flux hemodialysis: a systematic review","volume":"51","author":"Hui","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0038","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jcph.1727","article-title":"Evaluation and development of vancomycin dosing schemes to meet new AUC\/MIC targets in intermittent hemodialysis using Monte Carlo simulation techniques","volume":"61","author":"Lewis","year":"2021","journal-title":"J Clin Pharmacol J New Drugs"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0039","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/ajhp\/zxac066","article-title":"An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis","volume":"79","author":"Zelenitsky","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.clinthera.2025.01.001_bib0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/08971900231198927","article-title":"Development and Assessment of Vancomycin Dosing Utilizing AUC\/MIC Protocol in Patients With End-Stage Renal Disease (ESRD) on Intermittent Hemodialysis (IHD)","volume":"37","author":"Ables","year":"2024","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0041","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/nep.14144","article-title":"Vancomycin use for hemodialysis patients\u2014development of a new dosing protocol","volume":"28","author":"Ho","year":"2023","journal-title":"Nephrology"},{"key":"10.1016\/j.clinthera.2025.01.001_bib0042","first-page":"465","article-title":"An approach to optimize therapeutic vancomycin dosage in a hemodialysis population","volume":"109","author":"Gunning","year":"2016","journal-title":"Ir Med J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:22:14Z","timestamp":1741684934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0149291825000025"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vancomycin Dosing in Patients on Intermittent Hemodialysis\u2014A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}